Table 3. Association Between Adherence to NCCN Surveillance Guidelines and All-Cause Mortality in 230 Patientsa.
| Independent Variable | Adjusted Hazard Ratio (95% CI)b |
|---|---|
| Adherence to clinic guidelines in prior interval | 0.76 (0.28-2.05) |
| Age (every 10 y) | 1.75 (0.95-3.19) |
| Male | 0.83 (0.22-3.19) |
| Female | 1 [Reference] |
| Race/ethnicity | |
| White | 1 [Reference] |
| Asian | 1.32 (0.14-12.05) |
| Black | 2.22 (0.65-7.60) |
| Hispanic | 0.28 (0.04-2.12) |
| Smoking | |
| Non-smoker | 1 [Reference] |
| Ever smoked | 1.00 (0.43-2.32)) |
| Missing smoking data | 3.26 (0.27-38.95) |
| AJCC 8 stage | |
| Stage I | 1 [Reference] |
| Stage II | 2.04 (0.84-5.00) |
| Stage III | 3.21 (0.90-11.40) |
| Treatment modality | |
| Radiation therapy and chemotherapy, but no surgery | 1 [Reference] |
| Chemotherapy, surgery, and radiotherapy | 2.11 (0.57-7.83) |
| Surgery and radiotherapy (no chemotherapy) | 0.56 (0.12-2.74) |
| Radiotherapy only | 0.44 (0.03-7.03) |
| Surgery only | 0.36 (0.04-3.46) |
Abbreviations: AJCC 8, AJCC Cancer Staging Manual 8th edition; NCCN, National Comprehensive Cancer Network.
a
Two patients having less than 1 full interval of follow-up and 1 patient having unknown/other indication for race were excluded from this analysis.
b
Adjusted for age, sex, race/ethnicity, smoking status, AJCC 8 stage, treatment modality, as well as patient adherence to NCCN posttreatment clinic visit guidelines, which was constructed as a time-dependent variable.